In contrast, as another example, crizotinib significantly improved patients in the subgroup under a clinical trial in which only biomarker-positive patients with advanced anaplastic lymphoma kinase (ALK)-positive nonsquamous non-small cell lung cancer (NSCLC) were set as the targeted population [4]. Here, ALK is linked to non-small cell lung carcinoma.